patrick.net

ARRY tripled since my first recommendation, VCEL close to doubled. Both have much more room to run, ARRY has an incredibly large (mostly oncology) pipeline and partnerships as it transitions from development stage to commercial biotech and VCEL is turning towards profitability on ramping up their best available knee cartilage stem cell treatment and another one for heart failure in the waiting. Check em out, both far from being done yet.

#investing